Outcomes of lung cancer surgery in patients with COVID-19 history: a single center cohort study.
COVID-19
Lung cancer
SARS-CoV-2
Surgery
Treatment
Journal
General thoracic and cardiovascular surgery
ISSN: 1863-6713
Titre abrégé: Gen Thorac Cardiovasc Surg
Pays: Japan
ID NLM: 101303952
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
08
06
2022
accepted:
31
08
2022
pubmed:
15
9
2022
medline:
25
2
2023
entrez:
14
9
2022
Statut:
ppublish
Résumé
Coronavirus disease 2019 (COVID-19) can irreversibly damage the lungs and could possibly increase the risk of surgical treatment of lung cancer. The study aimed to assess the relationship between preoperative COVID-19 and complications and early outcomes of lung cancer surgery. This single-center cohort study included 444 patients who underwent lobectomy or segmentectomy for primary lung cancer from January 1, 2019 to December 31, 2021. The exclusion criteria were pneumonectomy, extended resection, and wedge resection. The groups of patients with (n = 72) and without (n = 372) the history of COVID-19 prior to surgery were compared. The groups were similar in terms of distribution of baseline, surgical and histopathological characteristics. The primary endpoint was the incidence of postoperative complications. Secondary endpoints were outcomes at discharge and at 90 days. The incidence of postoperative complications did not differ between the groups of patients with and without COVID-19 history (30.6% vs 29.3%, p = 0.831). Outcomes at discharge and at 90 days after surgery did not differ between the groups. Among the patients with and without prior COVID-19, 97.2 and 99.5% were alive at discharge (p = 0.125), and 97.2% and 98.1% ninety days after surgery (p = 0.644), respectively. Patients with COVID-19 history more often required re-drainage (6.9% v 2.2%, p = 0.044) and reoperation (5.6 v 1.3%, p = 0.042). COVID-19 history is not related to the general incidence of complications, outcomes at discharge from the hospital, and at 90-days after surgery.
Identifiants
pubmed: 36103107
doi: 10.1007/s11748-022-01871-x
pii: 10.1007/s11748-022-01871-x
pmc: PMC9471024
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-181Informations de copyright
© 2022. The Author(s).
Références
Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M. Global cancer observatory: cancer today. Lyon: International Agency for Research on Cancer; 2022.
Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J, et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1–21.
doi: 10.1093/annonc/mdx222
pubmed: 28881918
Dziedzic R, Marjanski T, Binczyk F, Polanska J, Sawicka W, Rzyman W. Favourable outcomes in patients with early-stage non-small-cell lung cancer operated on by video-assisted thoracoscopic surgery: a propensity score-matched analysis. Eur J Cardiothorac Surg. 2018;54:547–53.
pubmed: 29547899
Batchelor TJP, Rasburn NJ, Abdelnour-Berchtold E, Brunelli A, Cerfolio RJ, Gonzalez M, et al. Guidelines for enhanced recovery after lung surgery: recommendations of the enhanced recovery after surgery (ERAS
doi: 10.1093/ejcts/ezy301
pubmed: 30304509
Brunelli A, Salati M, Rocco G, Varela G, Van Raemdonck D, Decaluwe H, et al. European risk models for morbidity (EuroLung1) and mortality (EuroLung2) to predict outcome following anatomic lung resections: an analysis from the European society of thoracic surgeons database. Eur J Cardiothorac Surg. 2017;51:490–7.
pubmed: 27744321
Lembicz M, Gabryel P, Brajer-Luftmann B, Dyszkiewicz W, Batura-Gabryel H. Comorbidities with non-small cell lung cancer: is there an interdisciplinary consensus needed to qualify patients for surgical treatment? Ann Thorac Med. 2018;13:101–7.
doi: 10.4103/atm.ATM_274_17
pubmed: 29675061
pmcid: 5892084
Benker M, Citak N, Neuer T, Opitz I, Inci I. Impact of preoperative comorbidities on postoperative complication rate and outcome in surgically resected non-small cell lung cancer patients. Gen Thorac Cardiovasc Surg. 2022;70:248–56.
doi: 10.1007/s11748-021-01710-5
pubmed: 34554366
Ritchie H, Mathieu E, Rodés-Guirao L, Appel C, Giattino C, Ortiz-Ospina E, et al. (2022) Coronavirus Pandemic (COVID-19). https://ourworldindata.org/coronavirus .
Piwkowski C, Gabryel P, Orlowski TM, Kowalewski J, Kuzdzal J, Rzyman W. The impact of the COVID-19 pandemic on the surgical treatment of lung cancer. Pol Arch Med Wew. 2022;28:16191. https://doi.org/10.20452/pamw.16191.10 .
doi: 10.20452/pamw.16191.10
Zulfu A, Hamid ST, Elseed KA, Elmadhoun WM, Ahmed M, Ahmed MH. Coronavirus disease 2019 morbid pulmonary pathology: what did we learn from autopsy examinations? J Clin Transl Res. 2021;7:479–84.
pubmed: 34667895
pmcid: 8520706
Gattinoni L, Gattarello S, Steinberg I, Busana M, Palermo P, Lazzari S, et al. COVID-19 pneumonia: pathophysiology and management. Eur Respir Rev. 2021;30: 210138. https://doi.org/10.1183/16000617.0138-2021 .
doi: 10.1183/16000617.0138-2021
pubmed: 34670808
pmcid: 8527244
Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. 2020;20:425–34.
doi: 10.1016/S1473-3099(20)30086-4
pubmed: 32105637
pmcid: 7159053
Salehi S, Reddy S, Gholamrezanezhad A. Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19): what we know and what to expect. J Thorac Imaging. 2020;35:W87–9.
doi: 10.1097/RTI.0000000000000534
pubmed: 32404798
Sakai T, Azuma Y, Aoki K, Wakayama M, Miyoshi S, Kishi K, et al. Elective lung resection after treatment for COVID-19 pneumonia. Gen Thorac Cardiovasc Surg. 2021;69:1159–62.
doi: 10.1007/s11748-021-01630-4
pubmed: 33811611
pmcid: 8019292
Nefedov A, Mortada M, Novitskaya T, Patsyuk A, Kozak A, Yablonskii P. Lobectomy with pathological examination in lung cancer patients who recovered from COVID-19. Gen Thorac Cardiovasc Surg. 2021;69:1258–60.
doi: 10.1007/s11748-021-01632-2
pubmed: 33837476
pmcid: 8034765
COVID-19 Treatment Guidelines Panel. (2019) Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. https://www.covid19treatmentguidelines.nih.gov/ .
Collaborative CO, GlobalSurg C. Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia. 2021;76:748–58.
doi: 10.1111/anae.15458
Samson P, Patel A, Garrett T, Crabtree T, Kreisel D, Krupnick AS, et al. Effects of delayed surgical resection on short-term and long-term outcomes in clinical stage I non-small cell lung cancer. Ann Thorac Surg. 2015;99:1906–13.
doi: 10.1016/j.athoracsur.2015.02.022
pubmed: 25890663
pmcid: 4458152
Mandal S, Barnett J, Brill SE, Brown JS, Denneny EK, Hare SS, et al. ‘Long-COVID’: a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2021;76:396–8.
doi: 10.1136/thoraxjnl-2020-215818
pubmed: 33172844
Abou-Arab O, Bennis Y, Gauthier P, Boudot C, Bourdenet G, Gubler B, et al. Association between inflammation, angiopoietins, and disease severity in critically ill COVID-19 patients: a prospective study. Br J Anaesth. 2021;126:e127–30.
doi: 10.1016/j.bja.2020.12.017
pubmed: 33423740
Marjanski T, Wnuk D, Dziedzic R, Ostrowski M, Sawicka W, Rzyman W. 500 meters is a result of 6-minute walk test which differentiates patients with high and low risk of postoperative complications after lobectomy-a validation study. J Clin Med. 2021;10:1686. https://doi.org/10.3390/jcm10081686 .
doi: 10.3390/jcm10081686
pubmed: 33919996
pmcid: 8070994
Brunelli A, Kim AW, Berger KI, Addrizzo-Harris DJ. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2013;143:e166S – e190.
doi: 10.1378/chest.12-2395
pubmed: 23649437
Pezzi CM, Mallin K, Mendez AS, Greer Gay E, Putnam JB Jr. Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality. J Thorac Cardiovasc Surg. 2014;148:2269–77.
doi: 10.1016/j.jtcvs.2014.07.077
pubmed: 25172318
Powell HA, Tata LJ, Baldwin DR, Stanley RA, Khakwani A, Hubbard RB. Early mortality after surgical resection for lung cancer: an analysis of the English national lung cancer audit. Thorax. 2013;68:826–34.
doi: 10.1136/thoraxjnl-2012-203123
pubmed: 23687050
Desai AD, Lavelle M, Boursiquot BC, Wan EY. Long-term complications of COVID-19. Am J Physiol Cell Physiol. 2021;322:C1–11.
doi: 10.1152/ajpcell.00375.2021
pubmed: 34817268
pmcid: 8721906
Samson P, Guitron J, Reed MF, Hanseman DJ, Starnes SL. Predictors of conversion to thoracotomy for video-assisted thoracoscopic lobectomy: a retrospective analysis and the influence of computed tomography-based calcification assessment. J Thorac Cardiovasc Surg. 2013;145:1512–8.
doi: 10.1016/j.jtcvs.2012.05.028
pubmed: 22698554
Pan H, Chang R, Zhou Y, Gao Y, Cheng Y, Zhang C. Risk factors associated with prolonged air leak after video-assisted thoracic surgery pulmonary resection: a predictive model and meta-analysis. Ann Transl Med. 2019;7:103. https://doi.org/10.21037/atm.2019.02.17 .
doi: 10.21037/atm.2019.02.17
pubmed: 31019953
pmcid: 6462654
Salem AM, Al Khathlan N, Alharbi AF, Alghamdi T, AlDuilej S, Alghamdi M, et al. The long-term impact of COVID-19 pneumonia on the pulmonary function of survivors. J Gen Intern Med. 2021;14:3271–80.
doi: 10.2147/IJGM.S319436
Kalish H, Klumpp-Thomas C, Hunsberger S, Baus HA, Fay MP, Siripong N, et al. Undiagnosed SARS-CoV-2 seropositivity during the first 6 months of the COVID-19 pandemic in the United States. Sci Transl Med. 2021;13:eabh3826. https://doi.org/10.1126/scitranslmed.abh3826 .
doi: 10.1126/scitranslmed.abh3826
pubmed: 34158410
pmcid: 8432952